Recently, Indetek's independently developed ILDS® transdermal drug delivery technology platform has successfully obtained its first patent authorized by the China National Intellectual Property Administration (Patent No.: ZL202110438588.9), marking the recognition of Indetek's innovative capability and achievement in the field of transdermal drug delivery technology.
The ILDS® platform is a drug delivery technology based on a unique transdermal mechanism. It can significantly improve drug transdermal absorption efficiency and also provide sustained drug release effect. Its unique transdermal drug delivery mechanism allows various active pharmaceutical ingredients to achieve more efficient transdermal absorption comparing to typical topical formulations. Compared to traditional transdermal absorption methods, the absorption amount can be improved by order of magnitude. In addition to its capability of increasing drug transdermal absorption efficiency, ILDS® formulations are also well tolerated during in-vivo trials, greatly reducing the risk of skin irritation and allergic reactions. It is worth noted that the ILDS® platform can be widely used on different type of active pharmaceutical ingredients, including small molecule and large molecule biologics with various aqueous solubilities. Based on active pharmaceutical ingredient’s physical/chemical properties and indication, ILDS® platform can help to develop compound specific topical drug product formulation meeting diverse skin treatment or care needs.
The granting of ILDS® platform patent not only demonstrates Indetek’s technological innovation capabilities but also establishes a solid foundation for the company's future research and development work. Looking ahead, Indetek will continue to explore the potential of ILDS® drug delivery technology, expand its application in unexplored fields. With the help of ILDS® platform, Indetek is determined to provide patients with safer and more effective treatment options, and committed to continuous innovation and development of transdermal drug delivery technology.
